Jin-Hyoung Kang

12PUBLICATIONS
78CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsChemotherapyTranslation and interpretation studiesEpidemiological methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Aug 28, 2026
Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.

|Aug 05, 2026
Early and High-Dose Glucocorticoid Use and Survival in Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Multicenter Target Trial Emulation.

|Feb 27, 2026
Evolution of Immune Checkpoint Blockade in Metastatic NSCLC: A Narrative Review of Emerging Bispecific Antibodies and the Practical Challenges of Clinical Integration.

Jin Hyoung Kang

|Jan 13, 2026
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer.

Glenwood D Goss, Gail E Darling, Virginie Westeel

|Jun 28, 2023
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301.

Byoung Chul Cho, Myung-Ju Ahn, Jin Hyoung Kang

|Mar 22, 2023
Clinical experience of immune checkpoint inhibitor for a metastatic jejunal cancer patient with a high tumor mutational burden and low expression of programmed death-ligand 1.

Seo Ree Kim, Sang Hoon Chun, Ji Hyun Kim

Pageof 2

Frequent Collaborators

3 joint publications

SeungJin Bae

2 joint publications

Hee Yeon Lee

2 joint publications

Do Yeun Kim

2 joint publications

Hyerim Ha